Chronic hepatitis B virus (HBV) infection is a common cause of liver disease globally, with a
disproportionately high burden in South-East Asia. Vaccines and nucleoside or nucleotide …

Hepatitis B virus (HBV) specifically infects hepatocytes and causes severe liver diseases.
The HBV life cycle is unique in that the genomic DNA (relaxed-circular partially double …

Functional cure of chronic hepatitis B (CHB)—or hepatitis B surface antigen (HBsAg) loss
after 24 weeks off therapy—is now the goal of treatment, but is rarely achieved with current …

Current antiviral therapies, such as pegylated interferon-α and nucleos (t) ide analogues,
effectively improve the quality of life of patients with chronic hepatitis B. However, they can …

Hepatitis B virus (HBV) remains a major medical problem affecting at least 257 million
chronically infected patients who are at risk of developing serious, frequently fatal liver …

Hepatitis B virus (HBV) infection remains a major public health concern worldwide with
about 257 million individuals chronically infected. Current therapies can effectively control …

Hepatitis B virus (HBV) is a highly contagious pathogen that afflicts over a third of the world's
population, resulting in close to a million deaths annually. The formation and persistence of …

With a yearly death toll of 880,000, hepatitis B virus (HBV) remains a major health problem
worldwide, despite an effective prophylactic vaccine and well-tolerated, effective antivirals …

Hepatitis B virus (HBV) is a hepatotropic virus and an important human pathogen. There are
an estimated 296 million people in the world that are chronically infected by this virus, and …

Chronic hepatitis B virus (HBV) infections result in 887,000 deaths annually. The central
challenge in curing HBV is eradication of the stable covalently closed circular DNA …